Abstract:The antiphospholipid syndrome is an autoimmune disease characterized by thrombosis and pregnancy morbidity. The manifestations are caused by antibodies targeting cell membrane phospholipids and/or associated proteins. The triggers leading to these antibodies' production are unknown but recent work suggests cross-reactivity between the autoantigens and peptides produced by the intestinal microbiome. Work on how the autoantibodies could cause clinical manifestations implicates different mechanisms. Binding to surface proteins of different cell types can induce intracellular signaling leading to cell activation and tissue factor expression. Complement activation and neutrophil extracellular-traps are also involved, and recent evidence implicates endothelial protein C receptor-lysobisphosphatidic acid complex. Pregnancy is a high-risk situation for antiphospholipid syndrome patients due to the increased risk of thrombosis and obstetric complications. Epidemiological and clinical research on APS is hampered by heterogeneity in populations, testing and treatment strategies. About one in 10 to one in fifty APS pregnancies is complicated by thrombosis, despite treatment. Pregnant patients with prior thrombosis are prescribed therapeutic dose heparins and low dose aspirin. Without prior thrombosis a prophylactic dose is used. The most frequent obstetrical manifestation is recurrent early pregnancy loss. The association of APS antibodies with late pregnancy loss is stronger, however. Prevention of recurrence is achieved with aspirin and prophylactic dose heparin, although the evidence is of low certainty. The third obstetrical classifying manifestation comprises preterm delivery due to placenta-mediated complications and is treated in subsequent pregnancies with aspirin with or without prophylactic dose heparin, again based on low quality evidence. New therapies are under investigation.

Antiphospholipid syndrome presenting as recurrent coronary thrombosis: A case report

Antiphospholipid Syndrome: a Survey of Clinical Characters in Ten Cases

A case of repeated in-stent restenosis of coronary artery as a primary manifestation of seronegative antiphospholipid antibody syndrome

Spontaneous coronary artery dissection in a young patient with antiphospholipid syndrome

A case report of antiphospholipid syndrome

Antiphospholipid Syndrome Followed Idiopathic Retroperitoneal Fibrosis in the Same Patient: A Case Report and Review of Literature

An advanced understanding of the heterogeneous clinical features of “non-criteria” obstetric antiphospholipid syndrome: Two case reports and a literature review

Antiphospholipid syndrome presenting as extensive skin ulcers on unilateral lower extremity: a case report

Rare diagnosis of coexistent antiphospholipid syndrome and systemic lupus erythematosus in a male patient with successful management: a case report

Case Report: A Case of Recurrent Thrombosis in Pediatric Antiphospholipid Syndrome Associated with Pediatric Onset Systemic Lupus

Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management

Septal atrial thrombosis as a primary presentation of antiphospholipid syndrome in a patient with ANA-negative systemic lupus erythematosus: a case report

Interaction of antiphospholipid antibodies with endothelial cells in antiphospholipid syndrome

Evolution of Antiphospholipid Syndrome

Arterial Thrombosis in Antiphospholipid Syndrome (APS): Clinical Approach and Treatment. A Systematic Review.

Arterial thrombosis in antiphospholipid syndrome (APS): Clinical approach and treatment. A systematic review

The Issue of the Antiphospholipid Antibody Syndrome

The antiphospholipid syndrome - often overlooked cause of vascular occlusions?

Review of Antiphospholipid Syndrome and Its Cardiovascular Manifestation

[Analysis of Risk Factors in Development of Thrombosis in Patients with Antiphospholipid Syndrome].

Risk of Thrombosis, Pregnancy Morbidity or Death in Antiphospholipid Syndrome